TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01403038
Drug: elagolix
Normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elagolix plus Activella Dose Regimen 7 for 84 days
Study: NCT00152217
Drug: TS-1 (S-1)
Normalized name: Ts-1 (TN)
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
Study: NCT01127503
Drug: Metyrosine
Normalized name: Metyrosine
DrugBank: Metyrosine (DB00765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day \[2000 mg/day if metyrosine\]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
Study: NCT01715818
Drug: aleglitazar
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mcg orally daily
Study: NCT01024543
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II
Study: NCT01024543
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine
Study: NCT01041625
Drug: Apremilast (CC-10004)
Normalized name: Apremilast
DrugBank: Apremilast (DB05676)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apremilast 20 mg tablet PO administered BID over 12 weeks
Study: NCT01632891
Drug: Lopinavir/ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily.
Study: NCT01632891
Drug: Emtricitabine/tenofovir disoproxil fumarate
Normalized name: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily.
Study: NCT01632891
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received one 600 mg tablet of efavirenz orally once daily.
Study: NCT01632891
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If unable to take efavirenz, participants received on 200 mg tablet of nevirapine orally once daily.
Study: NCT01632891
Drug: Trimethoprim/sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily.
Study: NCT02183441
Drug: BI 1356
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183441
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00240071
Drug: Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
Study: NCT00240071
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or Selective Estrogen Receptor Modulator (SERM) (tamoxifen 20mg/d PO)
Study: NCT03294603
Drug: CC-220
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg \[14C\]-CC-220 will be administered as a single dose
Study: NCT04261270
Drug: ASC09F+Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ASC09F tablets:one tablet(400mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
Study: NCT04261270
Drug: Ritonavir+Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ritonavir tablet:three tablets(100mg/tablet)twice a day for 14 days;Oseltamivir tablet:75mg,once a day
Study: NCT04261270
Drug: Oseltamivir
Normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg ,once a day
Study: NCT03646721
Drug: DA-1241
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Part1\] Administration once daily for 28 days; Dose strength for each cohort (Cohort 1, 2 and 3) is planned as 50mg, 100mg and 200mg, respectively.~\[Part2\] Administration once daily for 56 days; Dose strength for each cohort (Cohort 4, 5 and 6) is planned as 25mg, 50mg and 100mg, respectively.~(Dose escalation and dose level decisions for subsequent cohorts will be made via interim dose escalation review meetings.)
Study: NCT03646721
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: \[Part2\] Administration of Sitagliptin 100mg once daily for 56 days.
Study: NCT02611258
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 20 mg to be taken orally once daily, for 3 months
Study: NCT02250209
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.~Number of cycles: 8 cycles.
Study: NCT02336477
Drug: Mexiletine
Normalized name: Mexiletine
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Blisters of 10 capsules of 200 mg mexiletine hydrochloride.~* Patients will receive gradual dose of the treatment as it would be done in clinical practice.~* Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.~* The duration of each treatment period is 18 days minimum (maximum 22 days).
Study: NCT01466270
Drug: donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02361528
Drug: Sargramostim: Leukine (Genzyme USA)
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
Study: NCT00996762
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1250 mg or 1500 mg lapatinib commercial tablet
Study: NCT02365636
Drug: TV-45070
Normalized name: Tv-3326 free base
DrugBank: Ladostigil (DB16213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV-45070 is an ointment applied topically twice daily to area of pain.
Study: NCT02993575
Drug: Flucloxacillin
Normalized name: Flucloxacillin
DrugBank: Flucloxacillin (DB00301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
Study: NCT01454934
Drug: Eribulin
Normalized name: Eribulin
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
Study: NCT01454934
Drug: TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days~* Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days~* Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days~* Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only).
Study: NCT04403321
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus will be given at 1mg bid with the target trough concentration to be 4-10 ng/mL.
Study: NCT04403321
Drug: Placebo (for Tacrolimus)
Normalized name: tacrolimus Granules for Oral Suspension
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo will be given at 1mg bid.
Study: NCT00148603
Drug: montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00033384
Drug: CI-1040
Normalized name: CI-1040
DrugBank: CI-1040 (DB12429)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02866838
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous
Study: NCT01782313
Drug: tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01800292
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
Study: NCT01697657
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study: NCT01697657
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
Study: NCT00826267
Drug: lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: lapatinib tablets 1500 mg daily
Study: NCT00826267
Drug: trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
Study: NCT02623803
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01091792
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
Study: NCT02559388
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00810953
Drug: Pentamidine
Normalized name: Pentamidine
DrugBank: Pentamidine (DB00738)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two dose of 6 mg/kg with or without standard chemotherapy.
Study: NCT01604343
Drug: Sirukumab
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
Study: NCT01604343
Drug: Sirukumab
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
Study: NCT01604343
Drug: Sirukumab
Normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
Study: NCT04264286
Drug: Prophylactic esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive prophylactic esmolol after the end of the surgery
Study: NCT00436748
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by subcutaneous or intravenous injection
Study: NCT02033733
Drug: Cisatracurium infusion
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.~Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group).
Study: NCT02033733
Drug: Cisatracurium prn bolus
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
Study: NCT01610791
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg iv every 4 weeks, total of 6 infusions
Study: NCT02579616
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
Study: NCT00661700
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
Study: NCT00215046
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug - dosage and frequency is based on size of patient and response to treatment.
Study: NCT03523117
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous iron
Study: NCT03523117
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral iron therapy
Study: NCT01996969
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
Study: NCT01217918
Drug: 5 mg
Normalized name: talc 25 MG
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg or placebo as material sparing tablet per day for 10 days
Study: NCT00357370
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, once daily, up to 12 weeks
Study: NCT03764722
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will initially receive a standard dose of 0.1 mcg/kgmc/min. In case of good tolerance of the drug - the dose will be increased to 0.2 mcg/kgmc/min. If hypotension SBP \<90 mmHg occurs, the dose will be reduced to 0.05 mcg / kgm / min. If the hypotension persists despite the reduction of the drug - the infusion will be terminated and the patient will be excluded from the study. The infusion will be terminated within 24 hours, the patient will be examined again 4 hours after the end of the infusion, by the attending physician and unless there are contraindications - discharged home.~Patients will be hospitalized every 4 weeks for the next 6 months.
Study: NCT00887458
Drug: Itraconazole 200 mg
Normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
Study: NCT01988571
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg tablet taken by mouth each morning for 24 months.
Study: NCT02187302
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02142530
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02142530
Drug: Belinostat
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02361567
Drug: Tramacet
Normalized name: triamcinolone acetonide Injectable Suspension [Tramacort]
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pain medication commonly used post-operatively
Study: NCT02361567
Drug: Percocet
Normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication commonly used post-operatively
Study: NCT00143611
Drug: Resatorvid
Normalized name: Resatorvid
DrugBank: Resatorvid (DB05943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
Study: NCT00143611
Drug: Resatorvid
Normalized name: Resatorvid
DrugBank: Resatorvid (DB05943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
Study: NCT04358497
Drug: Diosmin / Hesperidin
Normalized name: diosmin / hesperidin
DrugBank: Hesperidin (DB04703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best chronic medial treatment
Study: NCT03746522
Drug: Setmelanotide
Normalized name: Setmelanotide
DrugBank: Setmelanotide (DB11700)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC injection of setmelanotide
Study: NCT00887458
Drug: Itraconazole 300mg
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
Study: NCT00323414
Drug: Polyunsaturated fatty acid (Opti-EPA)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active experimental arm to patients with diabetes mellitus and non alcoholic steatohepatitis: Eicosapentaenoic acid (EPA):Docosahexaenoic acid (DHA)\[360 mg EPA and 240 DHA in each capsule\] 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
Study: NCT00606892
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline (1 mg per day) given for 4 days prior to laboratory session
Study: NCT00000327
Drug: Heroin Dependence
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03240627
Drug: LH-8
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-8 cutaneous solution
Study: NCT01205165
Drug: Adefor dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All enrolled subjects were enrolled to adefovir dipivoxil arm.
Study: NCT00472134
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
Study: NCT03728894
Drug: Midazolam-hydroxyzine with 100% O2
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received Oral Sedatives with 100% O2 ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
Study: NCT03728894
Drug: Midazolam-hydroxyzine with 50% N2O/O2
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received Oral Sedatives with 50% nitrous ,Behavior was assessed using the modified Houpt behavioral rating scale, by evaluating the videotapes of all patients at both the pretreatment and treatment phases.
Study: NCT00169143
Drug: Rituximab + ACVBP regimen plus Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02460770
Drug: Autologous mesenchymal stem cells
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
Study: NCT04029467
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: addition of dexmedetomidine to ropivacaine as an adjuvant in ESP block to assess wether or not it prolongs its duration of action
Study: NCT00648219
Drug: Olmesartan Medoxomil Tablets 40 mg
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg, single dose fed
Study: NCT00515827
Drug: Raltegravir (MK-0518)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg tablet taken orally twice daily
Study: NCT02327923
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
Study: NCT02327923
Drug: Esmolol
Normalized name: Esmolol
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
Study: NCT02327923
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inj. Paracetamol 1 gm IV at the time of induction